Expanding HCV Care and Treatment in Rural and Underserved Communities
December 2, 2019
June 20, 2020
Scroll to the Bottom of this Information to Begin this Course
Jointly provided by Rural Medical Education (RME) Collaborative and Boston University School of Medicine.
This activity is supported by an educational grant from AbbVie Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Nursing Contact Hour, of which 0.75 is eligible for pharmacology credit
All other health care professionals completing this course will be issued a statement of participation.
This activity is designed specifically for primary care clinicians and nurses practicing in rural and underserved areas.
Identification of individuals infected with hepatitis C virus (HCV) is key to prevention of this disease, as many of them are asymptomatic and unaware of their infection. Thus, knowledge of current HCV screening guidelines is critical, especially now that the recommendations have changed to address the higher incidence of HCV infection among injection drug users as a result of the opioid epidemic. With the advent of highly effective HCV treatments and the simplicity of new therapies, primary care clinicians can potentially provide more patients access to treatment and a cure. Being able to distinguish among the recommended therapies is essential to prevent progression to chronic HCV infection, which can lead to life-threatening illnesses such as cirrhosis and liver cancer. In this continuing education activity, experts in the field will review best practices for incorporating HCV screening and evidence-based treatment guidelines on the management of patients with HCV infection, with focus on follow-up and counseling of HCV-diagnosed patients and strategies for overcoming barriers to HCV care in rural and underserved areas.
The content for this activity was recorded on February 2, 2019. On September 4, 2019, the United States Preventive Services Task Force released an updated draft recommendation on screening for hepatitis C infection in adolescents and adults. Please click here for more information.
Upon completion of this activity, participants should be better able to:
- Apply current guidelines for age- and risk-based HCV screening
- Implement effective follow-up and counseling for patients with confirmed diagnosis of HCV infection
- Describe currently available and emerging treatment options for HCV infection
- Incorporate evidence-based treatment guidelines into the effective management of patients with HCV infection
Nancy S. Reau, MD (Program Chair)
Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Section Chief of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Donald M. Jensen, MD, FACP, FAASLD
Professor of Medicine
Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and RME Collaborative. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by RME Collaborative.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Contact Hours: 1.0 of which 0.75 is eligible for pharmacology credit.
Disclosures of Conflicts of Interest
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Nancy S. Reau, MD (Program Chair) has disclosed the following relationships: consultant for AbbVie, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., and Shire; contracted research support from GENFIT, Intercept Pharmaceuticals, Inc., and Shire.
Donald M. Jensen, MD (Co-Course Director) has no relevant financial conflicts to disclose.
Robert Lowe, MD, CME Course Director, Boston University School of Medicine is a consultant for GI Reviewers.
The following planning committee members for this activity have no conflicts to disclose:
Lizabeth Cline, MSN, CNE Course Advisor, Boston University School of Medicine
Joanna Krause, MPH, Program Manager, Boston University School of Medicine, CME
Carmela A. Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of Medicine
Kristin Della Volpe, Medical Writer, Scientific Affairs, Talem Health, LLC
Erica Rusie, PharmD, Scientific Director, Scientific Affairs, Talem Health, LLC
Disclosure of Unlabeled Use
Faculty members do not discuss unlabeled/investigational uses of a commercial product.
Instructions for Participation and Credit
In order to receive credit, participants must view the entire activity and complete the posttest and evaluation. Participants who receive a score of 75% or better will receive CME/CNE credit. A certificate of credit will be available for immediate download to those who successfully complete the posttest and evaluation.
For any CME or CNE accreditation questions, please email the BUSM CME office at firstname.lastname@example.org.
BUSM CME complies with the ADA and the rules and regulations thereof to make reasonable accommodations for our educational activities. If any participant in this educational activity is in need of accommodations, please contact BUSM CME at 617-358-5005.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
All programs, activities, and materials provided by Boston University Office of Continuing Medical Education or its associates are provided on the condition that they be used solely for educational purposes by qualified health care professionals. In no event shall Boston University or RME Collaborative be liable for any decision made or action taken in reliance on the information contained in the continuing medical education programs, activities or materials. In no event should the information contained in the program be used as a substitute for professional care. No physician-patient relationship is being established.
©Talem Health, LLC 2019. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.